Baird Medical Reports Strong Financial Performance
Total revenues surged to US$13.1 million, indicating a remarkable 13.8% year-over-year growth, while net income climbed to US$4.4 million, reflecting an impressive 85.8% increase.
2024 Financial Highlights
During the first half of 2024, Baird Medical has shown robust financial performance. Total revenues reached US$13.1 million, a significant increase from US$11.5 million the previous year. This growth showcases the company’s effective market strategy and commitment to innovation within the competitive medical industry.
Gross and Operating Profit Improvements
Gross profit in the same period experienced a substantial rise of 20.9%, amounting to US$11.5 million compared to US$9.5 million last year. Additionally, operating income rose to US$5.1 million, up 70.0% from US$3.0 million in 2023.
Strong Net Income Growth
The net income of Baird Medical soared by 85.8% to US$4.4 million from US$2.4 million in the prior year period, reflecting the company’s operational efficiency and strategic initiatives aimed at market expansion.
CEO's Perspective on Business Growth
Ms. Haimei Wu, the Founder and CEO of Baird Medical, shared insights on the company's progress: "Our preliminary results for the first half of 2024 reveal the strength of our core business and the initial traction we’re gaining in the U.S. market. With recent FDA clearances, we aim to expand our reach in the U.S. where our innovative microwave ablation technology presents a promising alternative to traditional thyroidectomy for patients with benign thyroid tumors."
Recent Developments
On October 1, 2024, Baird Medical announced the completion of a significant business combination with ExcelFin Acquisition Corp. Following this merger, the combined entity operates under the name Baird Medical Investment Holdings Limited, trading on Nasdaq under ticker symbols BDMD and BDMDW. This strategic move positions Baird Medical for further growth and investor engagement.
About Baird Medical
Founded in 2012 and based in Guangzhou, Baird Medical specializes in the development of microwave ablation (MWA) medical devices. The company has made an impact in both the Chinese market and the new U.S. market, with its proprietary technology targeting the treatment of both benign and malignant tumors.
Frequently Asked Questions
What are Baird Medical's recent financial results?
Baird Medical reported total revenues of US$13.1 million, with net income reaching US$4.4 million, showcasing significant growth.
What is the significance of the business combination?
The merger with ExcelFin Acquisition Corp allows Baird Medical to operate under a larger platform, enhancing its market presence and investor appeal.
How does Baird Medical's technology benefit patients?
The company’s microwave ablation technology offers a less invasive alternative to traditional surgery for treating benign thyroid tumors.
What is the company's strategy for market expansion?
Baird Medical aims to leverage its recent FDA clearances to broaden its footprint in the U.S. healthcare market.
Who can I contact for investor relations information?
For inquiries, Robin Yang is available at ICR, LLC, reachable at +1 (646) 308-1475 or via email.
